Researchers have identified that a tissue-based molecular test, known as Decipher, can predict which men with high-risk, localised prostate cancer benefit most from intensive hormone therapy.
Published in this week’s clinical findings, the study suggests this genomic approach could spare patients from unnecessary, aggressive treatments that often cause significant side effects.
Clinical Insights for Treatment Decisions
- Personalized Genomics: The Decipher test analyzes tumor tissue to assign a score, helping clinicians determine if a patient requires intensified hormone therapy like abiraterone or can safely avoid it.
- Reducing Toxicity: By identifying low-risk patients who would not benefit from aggressive protocols, doctors can avoid the long-term complications of unnecessary intensive treatment, such as incontinence and erectile dysfunction.
- Evidence-Based Validation: The findings are supported by data from the STAMPEDE clinical trial and a large real-world cohort of over 27,000 cases, demonstrating a consistent correlation between higher scores and disease progression.
Genomic Scoring in the STAMPEDE Trial
Prostate cancer remains the most commonly diagnosed cancer in the UK, yet the disease’s biological behavior varies significantly between individuals. Researchers at University College London (UCL) utilized the Decipher molecular test to assess 401 men with non-metastatic prostate cancer randomised within the STAMPEDE clinical trial, Healthcare Today reported.
The study found that for every 0.1 increase in a patient’s Decipher score, the risk of distant metastasis rose with an adjusted hazard ratio of 1.49, while the risk of prostate cancer mortality increased with a hazard ratio of 1.38.
“For men with very high-risk prostate cancer, preventing the cancer from spreading is critical, and understanding who benefits most from additional treatment can make a meaningful difference.”
said Sarah Howlett, lead researcher at the UCL Cancer Institute. “Our findings suggest that a genomic test could help personalise treatment. Men with high-risk disease but a low Decipher score have low rates of cancer spread, and could potentially be spared more intensive treatment, while men with a high score would be prioritised for it,” said Sarah Howlett, lead researcher at the UCL Cancer Institute.

Digital Tools and MRI Aim to Refine Diagnosis
Beyond molecular testing, the UK healthcare system is introducing digital tools to manage prostate cancer care. Prostate Cymru has launched an AI-powered resource trained on clinical guidelines from NICE and NHS Wales. “It has been rigorously trained on current guidelines from NICE, NHS Wales and Public Health bodies,” said Owen Pugsley of Prostate Cymru.
Parallel to these developments, the ReIMAGINE project is investigating how magnetic resonance imaging (MRI) can refine diagnostic pathways. “One of the biggest ongoing challenges in prostate cancer is that we still can't reliably predict which cancers will become life-threatening and which will remain low risk,” said Professor Mieke Van Hemelrijck of King's College London, who is involved in the ReIMAGINE project.
The project, which will launch its next phase on December 10, aims to link data from over 1,000 patients with NHS records to track long-term outcomes, as reported by the University College London news service.
| Metric | Clinical Significance |
|---|---|
| Decipher Score Increase (0.1) | Hazard Ratio: 1.49 (Metastasis) / 1.38 (Mortality) |
| Target Population | Men with high-risk, localized prostate cancer |
| Primary Objective | Differentiation between aggressive and indolent tumor biology |
Consult a Doctor If Experiencing Urinary Symptoms
While molecular testing and AI tools offer new avenues for precision, they do not replace standard diagnostic procedures like the Prostate-Specific Antigen (PSA) blood test or clinical biopsy.
Patients experiencing symptoms such as difficulty starting urination, weak urinary flow, or blood in the urine or semen should seek immediate consultation with a GP or urologist. These symptoms are not exclusive to cancer and can indicate benign prostatic hyperplasia (BPH) or other conditions that require professional evaluation.
Patients currently on active surveillance—a strategy where doctors monitor the cancer closely rather than treating it immediately—should discuss with their oncologist whether genomic testing is appropriate for their specific case.
As noted by Barry O’Carroll, a patient who underwent active surveillance before surgery, the uncertainty of cancer progression can feel like a “ticking time bomb,” making the development of these diagnostic tools essential for patient peace of mind and clinical accuracy.

References
- Cheshire Live: Cheshire survivor welcomes new trial to address one of the biggest challenges of prostate cancer.